CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 72 enrolled
Drug / intervention
Afatinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04206787
NCT04206787N/ACompleted
CompareCT.gov

Real-world Study on Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer (NSCLC)

Boehringer Ingelheim·observational·Posted Dec 20, 2019·Updated Feb 28, 2025

In Brief

An observational study evaluating Afatinib for Non-squamous, Non-Small Cell Lung Cancer. Completed, enrolled 72 participants across 10 sites.

Detailed Summary

This study aims to observe the sequential strategy with afatinib as first-line treatment and to find the optimal treatment strategy for long-term chemotherapy-free regimens in Chinese patients with EGFR-mutated advanced NSCLC. Furthermore, this study can also assess the effectiveness and safety of afatinib as first-line treatment.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNon-squamous, Non-Small Cell Lung Cancer
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedDec 20, 2019
Enrollment StartMay 20, 2020
Primary CompletionDec 18, 2023
Study CompletionDec 22, 2023
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 6.5 years ago

Interventions

Afatinibdrug

drug